2300 Lakeview Parkway, #700, Alpharetta, GA 30009, USA
Tel: +1 (508) 219-0200
POWERFUL EFFICACY TO FIGHT AGAINST RCC
FIRST-LINE TREATMENT In Management of Renal Cell Carcinoma
Practice Guidelines in Oncology 2017
First-line treatment of patients
with good or intermediate prognosis
Sunitinib is listed as a first-line therapy options for patients with relapsed or stage IV and surgically unresectable with predominantly clear cell renal cell carcinoma.
Only Sunitinib was listed as the “preferred” option for systemic therapy options for relapsed or stage IV and surgically unresectable with nonclear cell histology.
The usual dose is 50 mg once daily taken for 28 days (4 weeks), followed by 14 days (2 weeks) of rest (drug-free).
Dose modification renal cell carcinoma (RCC).
• Increase or reduce dose in 12.5-mg increments based on individual safety and tolerability.
• Concurrent CYP3A4 Inhibitors: Consider dose reduction to 37.5 mg once daily
• Concurrent CYP3A4 Inducers: Consider dose increase not to exceed 87.5 mg once daily
(Sunitinib)
(Sunitinib)
Multi-targeted receptor tyrosine kinase inhibitor.
• Sunitinib simultaneously inhibits PDGF and VEGF receptors, which play a role in both tumor cell proliferation and angiogenesis.
• Sunitinib induces tumor regression and inhibits angiogenesis and metastatic progression.
is perfectly equivalent to the reference drug.